Kremke B, Bergwitz C, Ahrens W, Schütt S, Schumacher M, Wagner V, Holterhus P-M, Jüppner H, Hiort O
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Endocrinology and Diabetology, University of Lübeck, Lübeck, Germany.
Exp Clin Endocrinol Diabetes. 2009 Feb;117(2):49-56. doi: 10.1055/s-2008-1076716. Epub 2008 Jun 3.
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is caused by mutations in SLC34A3, the gene encoding the renal sodium-phosphate co-transporter NaPi-IIc. Despite increased urinary calcium excretion, HHRH is typically not associated with kidney stones prior to treatment. However, here we describe two sisters, who displayed nephrolithiasis or nephrocalcinosis upon presentation. The index patient, II-4, presented with short stature, bone pain, and knee X-rays suggestive of mild rickets at age 8.5 years. Laboratory evaluation showed hypophosphatemia, elevated 1,25(OH) (2) vitamin D levels, and hypercalciuria, later also developing vitamin D deficiency. Her sister, II-6, had a low normal serum phosphorous level, biochemically vitamin D deficiency and no evidence for osteomalacia, but had undergone left nephro-ureterectomy at age 17 because of ureteral stricture secondary to renal calculi. Nucleotide sequence analysis of DNA from II-4 and II-6 revealed a homozygous missense mutation c.586G>A (p.G196R) in SLC34A3/NaPi-IIc. Ultrasonographic examinations prior to treatment showed grade I nephrocalcinosis for II-4, while II-6 had grade I-II nephrocalcinosis in her remaining kidney. Four siblings and the mother were heterozygous carriers of the mutation, but showed no biochemical abnormalities. With oral phosphate supplements, hypophosphatemia and hypercalciuria improved in both homozygous individuals. Renal calcifications that are presumably due to increased urinary calcium excretion can be the presenting finding in homozygous carriers of G196R in SLC34A3/NaPi-IIc, and some or all laboratory features of HHRH may be masked by vitamin D deficiency.
遗传性低磷性佝偻病伴高钙尿症(HHRH)由SLC34A3基因突变引起,该基因编码肾钠磷协同转运蛋白NaPi-IIc。尽管尿钙排泄增加,但HHRH在治疗前通常与肾结石无关。然而,我们在此描述了两姐妹,她们在就诊时出现了肾结石或肾钙质沉着症。先证者II-4在8.5岁时出现身材矮小、骨痛,膝关节X线检查提示轻度佝偻病。实验室检查显示低磷血症、1,25(OH)₂维生素D水平升高和高钙尿症,后来还出现了维生素D缺乏。她的妹妹II-6血清磷水平略低于正常,生化检查显示维生素D缺乏且无骨软化症证据,但因肾结石继发输尿管狭窄于17岁时接受了左肾输尿管切除术。对II-4和II-6的DNA进行核苷酸序列分析,发现SLC34A3/NaPi-IIc存在纯合错义突变c.586G>A(p.G196R)。治疗前的超声检查显示II-4为I级肾钙质沉着症,而II-6剩余肾脏为I-II级肾钙质沉着症。四名兄弟姐妹和母亲是该突变的杂合携带者,但未表现出生化异常。通过口服磷酸盐补充剂,两名纯合个体的低磷血症和高钙尿症均有所改善。推测由于尿钙排泄增加导致的肾钙化可能是SLC34A3/NaPi-IIc中G196R纯合携带者的首发表现,且HHRH的部分或全部实验室特征可能被维生素D缺乏所掩盖。